Docket #: S18-538
Method to treat neurodegenerative disorders by reducing lipid droplet accumulating microglia
Stanford researchers have identified lipid droplet accumulating microglia (LAM) in aging brains, proposing that these microglia play a role in neurodegenerative disease. LAM cells are defective in phagocytosis, produce high levels of reactive oxygen species and secrete pro-inflammatory cytokines. This technology provides methods of treating neurodegenerative disorders by reducing LAM. Methods for identifying LAM may also serve as novel targets for therapeutic development.
Stage of research
The inventors have identified LAM and shown that they are a novel state of microglia with a unique transcriptional signature and functional impairments in the aging brain. Additional development is ongoing.
Applications
- Treatment of age-related neurodegenerative diseases including:
- Alzheimer's disease
- Parkinson's disease
- Frontotemporal dementia
Advantages
- New therapeutic approach for treating neurodegenerative diseases
- Targets a subset of microglia known to be harmful to the brain
Publications
- J. Marschallinger, T. Iram, M. Zardeneta, …T. Wyss-Coray Lipid-droplet-accumulating microglia represent a dysfunctional and pro inflammatory state in the aging brain Nature Neuroscience 20 January 2020.
Related Links
Patents
- Published Application: WO2020146632
Similar Technologies
-
Cell Line for Optically-based Screening of Ion Channel Modulators S06-457Cell Line for Optically-based Screening of Ion Channel Modulators
-
Genetically-Targetable Optical Inactivation of Excitable Cells S06-398AGenetically-Targetable Optical Inactivation of Excitable Cells
-
Therapeutics for the Treatment of Parkinson's Disease S12-345Therapeutics for the Treatment of Parkinson's Disease